BG105253A - Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl)sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy)propylcarbamate - Google Patents

Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl)sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy)propylcarbamate

Info

Publication number: BG105253A
Authority: BG; Bulgaria
Prior art keywords: propylcarbamate; phosphonooxy; aminophenyl; furanyl; tetrahydro
Prior art date: 1998-07-18

Application number

BG105253A

Other languages

Bulgarian (bg)

English (en)

Inventor

Ian ARMITAGE

Andrew Searle

Hardev Singh

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-18

Filing date

2001-02-14

Publication date

2001-12-29

2001-02-14 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2001-12-29 Publication of BG105253A publication Critical patent/BG105253A/xx

Links

CDRQNDUZTKTSBS-NHALQGLQSA-L calcium;n-[(2s,3r,4s)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-cyclohex-2-en-1-yl-4-(furan-2-yl)-3-phosphonooxybutan-2-yl]carbamate Chemical compound [Ca+2].C([C@@H]([C@@H](OP(O)(O)=O)[C@H](N(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)C=1OC=CC=1)NC([O-])=O)C1CCCC=C1.C([C@@H]([C@@H](OP(O)(O)=O)[C@H](N(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)C=1OC=CC=1)NC([O-])=O)C1CCCC=C1 CDRQNDUZTKTSBS-NHALQGLQSA-L 0.000 title 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 2
229910052791 calcium Inorganic materials 0.000 abstract 1
239000011575 calcium Substances 0.000 abstract 1
UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
YNTOKMNHRPSGFU-UHFFFAOYSA-N n-Propyl carbamate Chemical compound CCCOC(N)=O YNTOKMNHRPSGFU-UHFFFAOYSA-N 0.000 abstract 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
241001430294 unidentified retrovirus Species 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BG105253A 1998-07-18 2001-02-14 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl)sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy)propylcarbamate BG105253A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9815567.4A GB9815567D0 (en)	1998-07-18	1998-07-18	Antiviral compound
PCT/EP1999/004991 WO2000004033A1 (en)	1998-07-18	1999-07-15	Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate

Publications (1)

Publication Number	Publication Date
BG105253A true BG105253A (en)	2001-12-29

Family

ID=10835689

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG105253A BG105253A (en)	1998-07-18	2001-02-14	Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl)sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy)propylcarbamate

Country Status (47)

Country	Link
US (3)	US6514953B1 (xx)
EP (2)	EP1240903A3 (xx)
JP (1)	JP3437553B2 (xx)
KR (1)	KR100694721B1 (xx)
CN (1)	CN1188422C (xx)
AP (1)	AP2001002039A0 (xx)
AR (1)	AR019388A1 (xx)
AT (1)	ATE229964T1 (xx)
AU (1)	AU766056B2 (xx)
BG (1)	BG105253A (xx)
BR (1)	BRPI9912156B8 (xx)
CA (1)	CA2337857C (xx)
CO (1)	CO5090836A1 (xx)
CZ (1)	CZ300447B6 (xx)
DE (1)	DE69904600T2 (xx)
DK (1)	DK1098898T3 (xx)
DZ (1)	DZ2845A1 (xx)
EA (1)	EA003191B1 (xx)
EE (1)	EE200100038A (xx)
ES (1)	ES2189450T3 (xx)
GB (1)	GB9815567D0 (xx)
GC (1)	GC0000105A (xx)
GE (1)	GEP20033030B (xx)
GT (1)	GT199900111A (xx)
HR (1)	HRP20010046A2 (xx)
HU (1)	HU229700B1 (xx)
ID (1)	ID28070A (xx)
IL (1)	IL140824A (xx)
IS (1)	IS5808A (xx)
JO (1)	JO2114B1 (xx)
MA (1)	MA26660A1 (xx)
MY (1)	MY122323A (xx)
NO (1)	NO329676B1 (xx)
NZ (1)	NZ509291A (xx)
OA (1)	OA11706A (xx)
PA (1)	PA8477801A1 (xx)
PE (1)	PE20000869A1 (xx)
PL (1)	PL195736B1 (xx)
PT (1)	PT1098898E (xx)
SK (1)	SK285311B6 (xx)
SV (1)	SV1999000096A (xx)
TN (1)	TNSN99145A1 (xx)
TR (1)	TR200100111T2 (xx)
TW (1)	TWI245770B (xx)
WO (1)	WO2000004033A1 (xx)
YU (1)	YU3401A (xx)
ZA (1)	ZA200100417B (xx)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9914821D0 (en) *	1999-06-24	1999-08-25	Glaxo Group Ltd	Compounds
ES2307533T3 (es) *	1999-10-06	2008-12-01	Tibotec Pharmaceuticals Ltd.	Hexahidrofuro(2,3)furan-3-il-n-(3-((1,3-benzodioxol-5-ilsulfonil)(is obuti)amino)-1-bencil-2-hidroxipropil carbamato como inhibidor de la proteasa retroviral.
PE20010635A1 (es) *	1999-10-08	2001-08-15	Smithkline Beecham Corp	Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
DK1560584T3 (da) *	2001-04-06	2009-05-18	Affinium Pharm Inc	Fab I inhibitorer
CN101041669A (zh) *	2002-04-26	2007-09-26	吉里德科学公司	非核苷逆转录酶抑制剂
DK1575951T3 (da) *	2002-12-06	2014-09-15	Debiopharm Int Sa	Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
CA2519429C (en)	2003-03-17	2013-08-06	Affinium Pharmaceuticals, Inc.	Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US7429565B2 (en)	2003-04-25	2008-09-30	Gilead Sciences, Inc.	Antiviral phosphonate analogs
WO2005002626A2 (en)	2003-04-25	2005-01-13	Gilead Sciences, Inc.	Therapeutic phosphonate compounds
US7407965B2 (en)	2003-04-25	2008-08-05	Gilead Sciences, Inc.	Phosphonate analogs for treating metabolic diseases
US7432261B2 (en)	2003-04-25	2008-10-07	Gilead Sciences, Inc.	Anti-inflammatory phosphonate compounds
US7427636B2 (en)	2003-04-25	2008-09-23	Gilead Sciences, Inc.	Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7300924B2 (en)	2003-04-25	2007-11-27	Gilead Sciences, Inc.	Anti-infective phosphonate analogs
EP1620109A2 (en)	2003-04-25	2006-02-01	Gilead Sciences, Inc.	Kinase inhibitor phosphonate conjugates
US7452901B2 (en)	2003-04-25	2008-11-18	Gilead Sciences, Inc.	Anti-cancer phosphonate analogs
US7470724B2 (en)	2003-04-25	2008-12-30	Gilead Sciences, Inc.	Phosphonate compounds having immuno-modulatory activity
US20080234288A1 (en) *	2003-09-30	2008-09-25	Kenneth Alan Simmen	Hcv Inhibiting Sulfonamides
WO2005044308A1 (en)	2003-10-24	2005-05-19	Gilead Sciences, Inc.	Phosphonate analogs of antimetabolites
WO2005044279A1 (en)	2003-10-24	2005-05-19	Gilead Sciences, Inc.	Purine nucleoside phosphonate conjugates
US7273717B2 (en)	2003-10-24	2007-09-25	Gilead Sciences, Inc.	Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B
MXPA06006899A (es)	2003-12-22	2006-09-04	Gilead Sciences Inc	Derivados de carbovir y abacavir 4'-sustituidos asi como compuestos relacionados con actividad antiviral de virus de inmunodeficiencia humana y virus de la hepatitis c.
KR101299399B1 (ko)	2004-06-04	2013-08-22	아피늄 파마슈티컬스, 인크.	치료제, 및 그의 제조 및 사용 방법
HRP20070078A2 (hr)	2004-07-27	2007-05-31	Gilead Sciences	Fosfonatni analozi spojeva koji inhibiraju hiv
JP5116479B2 (ja)	2004-11-26	2013-01-09	ユーシーエルビジネスピーエルシー	オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物
US20090156578A1 (en) *	2005-12-05	2009-06-18	PAULS Henry	3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
WO2008009122A1 (en)	2006-07-20	2008-01-24	Affinium Pharmaceuticals, Inc.	Acrylamide derivatives as fab i inhibitors
EP2125802A4 (en) *	2007-02-16	2014-08-20	Debiopharm Int Sa	SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
CN102816111B (zh)	2007-03-12	2014-08-06	尼克塔治疗公司	低聚物-蛋白酶抑制剂偶联物
EP2262538B1 (en) *	2008-03-12	2014-12-10	Nektar Therapeutics	Oligomer-amino acid conjugate
PT2307435E (pt)	2008-07-08	2012-09-19	Gilead Sciences Inc	Sais de compostos inibidores de vih
CA2998344C (en) *	2009-04-03	2020-06-02	Ocera Therapeutics, Inc.	L-ornithine phenyl acetate and methods of making thereof
US20120135965A1 (en) *	2009-05-20	2012-05-31	Ranbaxy Laboratories Limited	Amorphous fosamprenavir calcium
US20120157526A1 (en)	2009-06-08	2012-06-21	Ucl Business Plc	Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
EP2440249A2 (en)	2009-06-12	2012-04-18	Nektar Therapeutics	Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
WO2011001383A1 (en)	2009-06-30	2011-01-06	Ranbaxy Laboratories Limited	Crystalline form of fosamprenavir calcium
AU2010296846B2 (en) *	2009-09-16	2013-11-28	Sun Pharmaceutical Industries Limited	Process for the preparation of fosamprenavir calcium
EP2507250A1 (en) *	2010-01-07	2012-10-10	Pliva Hrvastka D.O.O.	Solid state forms of fosamprenavir calcium salt and process for preparation thereof
SMT201800290T1 (it)	2010-01-27	2018-07-17	Viiv Healthcare Co	Terapia antivirale
US20110224443A1 (en) *	2010-03-15	2011-09-15	Venkata Naga Brahmeshwara Rao Mandava	Preparation of fosamprenavir calcium
WO2011114212A1 (en)	2010-03-19	2011-09-22	Lupin Limited	Ammonium, calcium and tris salts of fosamprenavir
US20130211108A1 (en)	2010-06-18	2013-08-15	Mylan Laboratories Ltd	Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts
US8877947B2 (en)	2010-09-10	2014-11-04	Lupin Limited	Process for preparation of substantially pure fosamprenavir calcium and its intermediates
JP6087284B2 (ja)	2010-10-06	2017-03-01	オセラセラピューティクス，インコーポレイテッド	Ｌ−オルニチンフェニルアセテートを製造するための方法
CN102453053B (zh) *	2010-10-29	2014-11-26	浙江九洲药业股份有限公司	一种福沙那韦钙晶体及其制备方法
CN102453054B (zh) *	2010-10-29	2015-06-10	浙江九洲药业股份有限公司	一种福沙那韦衍生物的制备方法及相关中间体
WO2012085625A1 (en)	2010-12-21	2012-06-28	Lupin Limited	Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
JP2014513044A (ja) *	2011-02-10	2014-05-29	マイランラボラトリーズリミテッド	ホスアンプレナビルカルシウム結晶およびその調製方法
WO2013011485A1 (en)	2011-07-20	2013-01-24	Ranbaxy Laboratories Limited	Process for the preparation of sulfonamides useful as retroviral protease inhibitors
US9233943B2 (en)	2012-01-10	2016-01-12	Council Of Scientific & Industrial Research	Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir
BR122021020778B1 (pt)	2012-06-19	2022-07-12	Debiopharm International Sa	Derivados de pró-fármaco de (e)-n-metil-n-((3-metilbenzofuran-2-il) metil)-3-(7-oxo-5,6,7,8-tetraidro- 1, 8- naftirindin-3-il) acrilamida
CN107206021B (zh)	2014-11-24	2021-09-03	Ucl商业有限公司	使用降氨疗法治疗与肝星状细胞激活相关的疾病
US10835506B2 (en)	2015-08-18	2020-11-17	Ocera Therapeutics, Inc.	Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
SI3419628T1 (sl)	2016-02-26	2021-03-31	Debiopharm International Sa	Zdravilo za zdravljenje infekcij diabetičnega stopala
JP7126520B2 (ja)	2017-05-11	2022-08-26	オセラセラピューティクス，インコーポレイテッド	Ｌ－オルニチンフェニルアセテートを製造する方法
WO2019027920A1 (en)	2017-08-01	2019-02-07	Gilead Sciences, Inc.	CRYSTALLINE FORMS OF ETHYL ((S) - (((((2R, 5R) -5- (6-AMINO-9H-PURIN-9-YL) -4-FLUORO-2,5-DIHYDROFURAN-2-YL) OXY ) METHYL) (PHENOXY) PHOSPHORYL) -L-ALANINATE (GS-9131) FOR THE TREATMENT OF VIRAL INFECTIONS
PH12021551922A1 (en)	2019-02-14	2022-05-23	Debiopharm Int Sa	Afabicin formulation, method for making the same
UA129222C2 (uk)	2019-06-14	2025-02-12	Дебіофарм Інтернешнл С.А.	Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2698826A (en) *	1951-02-13	1955-01-04	Merco Centrifugal Co	Alcohol manufacturing process
US3437267A (en) *	1966-03-24	1969-04-08	Alfa Laval Ab	Centrifuge
JPH0244315B2 (ja) *	1982-06-14	1990-10-03	Microbial Chem Res Found	Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en)	1992-09-08	1998-03-03	Vertex Pharmaceuticals Incorporated	THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) *	1994-06-03	2002-10-15	Дж.Д. Сьорль Енд Ко	Спосіб лікування ретровірусних інфекцій
AU2010299A (en) *	1997-12-24	1999-07-19	Vertex Pharmaceuticals Incorporated	Prodrugs os aspartyl protease inhibitors
US6436989B1 (en) *	1997-12-24	2002-08-20	Vertex Pharmaceuticals, Incorporated	Prodrugs of aspartyl protease inhibitors
HUP0101598A3 (en) *	1997-12-24	2002-08-28	Vertex Pharmaceuticals Inc Cam	Prodrugs of aspartyl protease inhibitors and medicaments containing them
GB9812189D0 (en) *	1998-06-05	1998-08-05	Glaxo Group Ltd	Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) *	1998-09-28	2000-04-17	Glaxo Group Limited	Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
CA2346131C (en) *	1998-11-04	2013-01-15	Pharmacia & Upjohn Company	Method for improving the pharmacokinetics of tipranavir
CZ20002364A3 (cs) *	1998-12-23	2000-11-15	Vertex Pharmaceuticals Incorporated	Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) *	1999-06-24	1999-08-25	Glaxo Group Ltd	Compounds
US6642237B1 (en) *	1999-11-24	2003-11-04	Merck & Co., Inc.	Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof

1998
- 1998-07-18 GB GBGB9815567.4A patent/GB9815567D0/en not_active Ceased
1999
- 1999-07-14 GC GCP1999203 patent/GC0000105A/xx active
- 1999-07-14 AR ARP990103446A patent/AR019388A1/es not_active Application Discontinuation
- 1999-07-14 DZ DZ990145A patent/DZ2845A1/xx active
- 1999-07-15 OA OA1200100016A patent/OA11706A/fr unknown
- 1999-07-15 PL PL99345620A patent/PL195736B1/pl unknown
- 1999-07-15 EP EP02013136A patent/EP1240903A3/en not_active Withdrawn
- 1999-07-15 EE EEP200100038A patent/EE200100038A/xx unknown
- 1999-07-15 ID IDW20010145A patent/ID28070A/id unknown
- 1999-07-15 AU AU50379/99A patent/AU766056B2/en not_active Expired
- 1999-07-15 PT PT99934698T patent/PT1098898E/pt unknown
- 1999-07-15 BR BRPI9912156A patent/BRPI9912156B8/pt not_active IP Right Cessation
- 1999-07-15 AT AT99934698T patent/ATE229964T1/de active
- 1999-07-15 JP JP2000560139A patent/JP3437553B2/ja not_active Expired - Lifetime
- 1999-07-15 PE PE1999000714A patent/PE20000869A1/es not_active Application Discontinuation
- 1999-07-15 EP EP99934698A patent/EP1098898B1/en not_active Expired - Lifetime
- 1999-07-15 CN CNB998108383A patent/CN1188422C/zh not_active Expired - Lifetime
- 1999-07-15 ES ES99934698T patent/ES2189450T3/es not_active Expired - Lifetime
- 1999-07-15 MA MA25684A patent/MA26660A1/fr unknown
- 1999-07-15 GT GT199900111A patent/GT199900111A/es unknown
- 1999-07-15 WO PCT/EP1999/004991 patent/WO2000004033A1/en not_active Ceased
- 1999-07-15 TR TR2001/00111T patent/TR200100111T2/xx unknown
- 1999-07-15 MY MYPI99002983A patent/MY122323A/en unknown
- 1999-07-15 DK DK99934698T patent/DK1098898T3/da active
- 1999-07-15 DE DE69904600T patent/DE69904600T2/de not_active Expired - Lifetime
- 1999-07-15 TN TNTNSN99145A patent/TNSN99145A1/fr unknown
- 1999-07-15 HR HR20010046A patent/HRP20010046A2/hr not_active Application Discontinuation
- 1999-07-15 HU HU0103432A patent/HU229700B1/hu unknown
- 1999-07-15 CA CA2337857A patent/CA2337857C/en not_active Expired - Lifetime
- 1999-07-15 AP APAP/P/2001/002039A patent/AP2001002039A0/en unknown
- 1999-07-15 SK SK76-2001A patent/SK285311B6/sk not_active IP Right Cessation
- 1999-07-15 US US09/744,051 patent/US6514953B1/en not_active Expired - Lifetime
- 1999-07-15 SV SV1999000096A patent/SV1999000096A/es not_active Application Discontinuation
- 1999-07-15 EA EA200100053A patent/EA003191B1/ru not_active IP Right Cessation
- 1999-07-15 JO JO19992114A patent/JO2114B1/en active
- 1999-07-15 KR KR1020017000740A patent/KR100694721B1/ko not_active Expired - Lifetime
- 1999-07-15 YU YU3401A patent/YU3401A/sh unknown
- 1999-07-15 CO CO99044882A patent/CO5090836A1/es unknown
- 1999-07-15 CZ CZ20010219A patent/CZ300447B6/cs not_active IP Right Cessation
- 1999-07-15 GE GEAP19995716A patent/GEP20033030B/en unknown
- 1999-07-15 IL IL14082499A patent/IL140824A/en not_active IP Right Cessation
- 1999-07-15 NZ NZ509291A patent/NZ509291A/en not_active IP Right Cessation
- 1999-07-16 PA PA19998477801A patent/PA8477801A1/es unknown
- 1999-08-06 TW TW088113428A patent/TWI245770B/zh not_active IP Right Cessation
2001
- 2001-01-12 IS IS5808A patent/IS5808A/is unknown
- 2001-01-15 ZA ZA200100417A patent/ZA200100417B/en unknown
- 2001-01-17 NO NO20010282A patent/NO329676B1/no not_active IP Right Cessation
- 2001-02-14 BG BG105253A patent/BG105253A/xx unknown
2002
- 2002-11-25 US US10/303,213 patent/US20030100537A1/en not_active Abandoned
- 2002-11-25 US US10/303,366 patent/US20030096795A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2189450T3 (es)	2003-07-01
TR200100111T2 (tr)	2002-02-21
BR9912156A (pt)	2001-04-10
GEP20033030B (en)	2003-07-25
CN1188422C (zh)	2005-02-09
NO20010282L (no)	2001-03-07
PL345620A1 (en)	2002-01-02
KR100694721B1 (ko)	2007-03-15
GB9815567D0 (en)	1998-09-16
HU229700B1 (en)	2014-05-28
IL140824A0 (en)	2002-02-10
YU3401A (sh)	2005-06-10
PE20000869A1 (es)	2000-09-08
EP1098898B1 (en)	2002-12-18
CA2337857A1 (en)	2000-01-27
US20030096795A1 (en)	2003-05-22
US6514953B1 (en)	2003-02-04
EA003191B1 (ru)	2003-02-27
PL195736B1 (pl)	2007-10-31
CZ2001219A3 (cs)	2001-07-11
JP3437553B2 (ja)	2003-08-18
TWI245770B (en)	2005-12-21
NZ509291A (en)	2003-05-30
BRPI9912156B8 (pt)	2021-05-25
GT199900111A (es)	2001-01-05
EE200100038A (et)	2002-06-17
DE69904600D1 (de)	2003-01-30
SK762001A3 (en)	2001-10-08
JO2114B1 (en)	2000-05-21
MY122323A (en)	2006-04-29
ATE229964T1 (de)	2003-01-15
HUP0103432A2 (hu)	2002-04-29
PT1098898E (pt)	2003-04-30
HK1034261A1 (en)	2001-10-19
IL140824A (en)	2004-09-27
NO329676B1 (no)	2010-11-29
CN1324363A (zh)	2001-11-28
ID28070A (id)	2001-05-03
SK285311B6 (sk)	2006-10-05
DZ2845A1 (fr)	2003-12-01
CZ300447B6 (cs)	2009-05-20
ZA200100417B (en)	2002-02-27
PA8477801A1 (es)	2000-05-24
MA26660A1 (fr)	2004-12-20
SV1999000096A (es)	2000-07-06
EP1240903A3 (en)	2003-02-12
NO20010282D0 (no)	2001-01-17
AU766056B2 (en)	2003-10-09
GC0000105A (en)	2005-06-29
TNSN99145A1 (fr)	2005-11-10
CO5090836A1 (es)	2001-10-30
AU5037999A (en)	2000-02-07
BRPI9912156B1 (pt)	2016-07-26
EA200100053A1 (ru)	2001-08-27
HUP0103432A3 (en)	2003-01-28
IS5808A (is)	2001-01-12
HRP20010046A2 (en)	2002-02-28
EP1098898A1 (en)	2001-05-16
CA2337857C (en)	2011-01-25
DE69904600T2 (de)	2003-11-13
JP2003521447A (ja)	2003-07-15
KR20010071952A (ko)	2001-07-31
US20030100537A1 (en)	2003-05-29
OA11706A (en)	2005-01-13
WO2000004033A1 (en)	2000-01-27
DK1098898T3 (da)	2003-04-07
AP2001002039A0 (en)	2001-03-31
EP1240903A2 (en)	2002-09-18
AR019388A1 (es)	2002-02-13

Publication	Publication Date	Title
BG105253A (en)	2001-12-29	Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl)sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
AU5812400A (en)	2001-01-02	Carrier-drug conjugate
MY125821A (en)	2006-08-30	Pharmaceutical composition of topiramate
AU2003217055A1 (en)	2003-10-13	Protein for use in hypoxia related conditions
BR9808938A (pt)	2000-08-01	Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um distúrbio ou doença de um corpo de animal vivo e para a preparação de um composto, e, uso de bloqueadores de canal de cloreto
EP2241329A3 (en)	2011-03-09	Anti-interleukin-9 antibody or anti-interleukin-9 receptor antibody for treating bronchial hyper-responsiveness
MY120683A (en)	2005-11-30	New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals.
AU6624896A (en)	1997-03-05	Pharmaceutical composition
WO2001000635A3 (en)	2003-04-17	Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
MX9604762A (es)	1997-04-30	Nuevas sulfonamidas y procedimiento para su preparacion.
GB9516967D0 (en)	1995-10-18	Pharmaceutical composition
EP1607399A3 (en)	2006-01-04	BIS-(N,N'-BIS-(2-Haloethyl)Amino) Phosphoramidates as antitumor agents
TH69155A3 (th)	2005-06-14	แคลเซียม (3s) เททระไฮโดร-3-ฟิวแรนิล (1s,2r)-3-[[(4-อะมิโนฟีนิล)ซัลโฟนิล](ไอโซบิวทิล)อะมิโน]-1-เบนซิล-2-(ฟอสโฟโนออกซี)โพรพิลคาร์บาเมต
BG104829A (en)	2001-05-31	Crystalline forms of 1s-[1alpha (2s,3r), 9alpha]-6, 10-dioxo-n- (2-ethoxy-5-oxo-tetrahydro-3-furanyl-9[[(1-isoquinolyl)carbonyl]-a mino]octahydro-6h-pyridazino[1,2-a][1,2]diazepin-1-carboxamide
TH56922C3 (th)	2017-08-23	แคลเซียม (3s) เททระไฮโดร-3-ฟิวแรนิล (1s,2r)-3-[[(4-อะมิโนฟีนิล)ซัลโฟนิล](ไอโซบิวทิล)อะมิโน]-1-เบนซิล-2-(ฟอสโฟโนออกซี)โพรพิลคาร์บาเมต
SI1098898T1 (en)	2003-08-31	Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-(((4-aminophenyl) sulfonyl) (isobutyl) amino) -1-benzyl-2- (phosphonooxy) propylcarbamate
TW200501942A (en)	2005-01-16	Pharmaceutical compositions
NZ323964A (en)	2000-01-28	4,10beta-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-1-hydroxy-9-oxo-19-nor-cy clopropa[g]tax-11-ene-13alpha-yl
MX9802268A (es)	1998-08-30	Nuevos derivados de la substancia pf1022 de ciclodepsipeptido.
MX9709684A (es)	1998-06-28	Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.
MX9606264A (es)	1997-10-31	Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol como sustancias farmacologicas activas.